Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JUOJJ
ADC Name
MHB-036C
Synonyms
MHB 036C; MHB-036C; MHB036C; ZG 157; ZG-157; ZG157
   Click to Show/Hide
Organization
Minghui Pharmaceutical (Hangzhou) Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Tumor-associated calcium signal transducer 2 (TROP2)
  Antigen Info 
Payload Name
MH30010008
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05642949
Phase 1/2
Phase 1/2, multi-center, open-label, dose escalation and cohort expansion study to evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB036C in participants with advanced or metastatic solid tumors.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05642949  Clinical Status Phase 1/2
Clinical Description Phase 1/2, multi-center, open-label, dose escalation and cohort expansion study to evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB036C in participants with advanced or metastatic solid tumors.
References
Ref 1 Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors, NCT05642949